在三阴性乳腺癌中新兴的蛋白质点:超越常规疗法
Andrea Previtali1, Isabella Guardamagna2, Silvia Calandra1
1Department of Molecular Medicine, University of Pavia, 27100 Pavia, Italy.
Cancers
|February 27, 2026
概括
三阴性乳腺癌 (TNBC) 是具有侵略性的,但新的向疗法显示出希望. 本综述涵盖了新兴的治疗方法,如抗体-药物合物和途径抑制剂,以克服耐药性并改善TNBC患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 三阴性乳腺癌 (TNBC) 是一种缺乏ER,PR和HER2表达的侵袭性亚型,具有重大治疗挑战.
- 化学疗法和免疫疗法等传统治疗方法经常面临抗药性和复发性,需要新的治疗策略.
- 蛋白质组学,结构生物学和向蛋白质降解方面的进展正在确定TNBC的新目标.
研究的目的:
- 审查TNBC目前和新兴的治疗策略.
- 专注于针对瘤异质性和耐药机制的有针对性的方法.
- 为不断发展的TNBC治疗领域提供最新的概述.
主要方法:
- 总结了针对性治疗的最新进展,包括免疫检查点抑制剂,PARP抑制剂,抗体药物联合剂和途径抑制剂.
- 检查各种向药物的临床试验结果.
- 探索通过OMIC方法识别的新目标,以及瘤代谢和微环境的作用.
- 概述创新的放射治疗策略.
主要成果:
- 向疗法,包括免疫检查点抑制剂,PARP抑制剂,Trop-2-定向抗体-药物联合体和途径抑制剂,在临床试验中显示出潜力.
- 综合性omics方法正在确定新的治疗点.
- 瘤代谢和微环境显著影响治疗疗效.
- 正在开发创新的放射治疗策略.
结论:
- 在TNBC治疗的景观正在迅速发展,有希望的有针对性的方法.
- 生物标志物驱动的策略对于开发下一代治疗方法至关重要.
- 解决瘤异质性和抵抗机制是改善患者治疗结果的关键.
- 进一步研究新的标,新陈代谢,微环境和放射治疗整合是有必要的.
更多相关视频
03:08Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
Published on: October 3, 2025
1.0K
07:48Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
Published on: December 26, 2016
11.9K
相关概念视频
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Mitogens and the Cell Cycle
8.2K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
mTOR Signaling and Cancer Progression
4.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.9K
Transducer Mechanism: Enzyme-Linked Receptors
4.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
4.5K
Protein Networks
4.6K
An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
4.6K
